Vanessa Abella

Vanessa Abella

Auto-generated profile, based on publicly available information

Vanessa Abella

SERGAS (Servizo Galego de Saude) and IDIS (Instituto de Investigación Sanitaria de Santiago), the NEIRID Lab (Neuroendocrine Interactions in Rheumatology and Inflammatory Diseases), Research Laboratory 9, Santiago University Clinical Hospital, Santiago de Compostela, Spain

Research Focus & Metrics

Academic Career Length

15Years (2012-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 January 2014 in Journal of Immunology Research
Verified
Journal Article
Open access
PDF file
VAVanessa Abella
Vanessa Abella
MSMorena Scotece
Morena Scotece
Javier Conde ArandaJavier Conde Aranda
Javier Conde Aranda
VLVerónica López
Verónica López
VLVerónica Lazzaro
Verónica Lazzaro
Oreste GualilloOreste Gualillo
Oreste Gualillo
The metabolic syndrome (MetS) is a cluster of cardiometabolic disorders that result from the increasing prevalence of obesity. The major components of MetS include insulin resistance, central obesity, dyslipidemia, and hypertension. MetS identifies the central obesity with increased risk for cardiovascular diseases (CVDs) and type-2 diabetes mellitus (T2DM). Patients with rheumatic diseases, such as rheumatoid arthritis, osteoarthritis, systemic lupus erythematosus, and ankylosing spondylitis, have increased prevalence of CVDs. Moreover, CVD risk is increased when obesity is present in these patients. However, traditional cardiovascular risk factors do not completely explain the enhanced cardiovascular risk in this population. Thus, MetS and the altered secretion patterns of proinflammatory adipokines present in obesity could be the link between CVDs and rheumatic diseases. Furthermore, adipokines have been linked to the pathogenesis of MetS and its comorbidities through their effects on vascular function and inflammation. In the present paper, we review recent evidence of the role played by adipokines in the modulation of MetS in the general population, and in patients with rheumatic diseases.

1 March 2014 in Annals of the Rheumatic Diseases
Verified
Journal Article
Closed access
PDF file
Javier Conde ArandaJavier Conde Aranda
Javier Conde Aranda
MSMorena Scotece
Morena Scotece
VLVerónica López
Verónica López
VAVanessa Abella
Vanessa Abella
MHMiguel Hermida
Miguel Hermida
Oreste GualilloOreste Gualillo
Oreste Gualillo

25 August 2015 in PLOS ONE
Verified
Journal Article
Open access
PDF file
ASAnna Santoro
Anna Santoro
Javier Conde ArandaJavier Conde Aranda
Javier Conde Aranda
MSMorena Scotece
Morena Scotece
VAVanessa Abella
Vanessa Abella
ALAna Lois
Ana Lois
Oreste GualilloOreste Gualillo
Oreste Gualillo
Osteoarthritis (OA) is a chronic joint disease, characterized by a progressive loss of articular cartilage. During OA, proinflammatory cytokines, such as interleukin IL-1, induce the expression of matrix metalloproteinases (MMPs) in chondrocytes, contributing thus to the extracellular matrix (ECM) degradation. Members of Serpine family, including plasminogen activator inhibitors have been reported to participate in ECM regulation. The aim of this study was to assess the expression of serpin peptidase inhibitor clade E member 2 (SERPINE2), under basal conditions and in response to increasing doses of IL-1α, in human cultured chondrocytes. We also examined the effects of SERPINE2 on IL-1α-induced MMP-13 expression. For completeness, the signaling pathway involved in this process was also explored. SERPINE2 mRNA and protein expression were evaluated by RT-qPCR and western blot analysis in human T/C-28a2 cell line and human primary chondrocytes. These cells were treated with human recombinant SERPINE2, alone or in combination with IL-1α. ERK 1/2, NFκB and AP-1 activation were assessed by western blot analysis. Human cultured chondrocytes express SERPINE2 in basal condition. This expression increased in response to IL-1α stimulation. In addition, recombinant SERPINE2 induced a clear inhibition of MMP-13 expression in IL-1α-stimulated chondrocytes. This inhibitory effect is likely regulated through a pathway involving ERK 1/2, NF-κB and AP-1. Taken together, these data demonstrate that SERPINE2 might prevent cartilage catabolism by inhibiting the expression of MMP-13, one of the most relevant collagenases, involved in cartilage breakdown in OA.

29 May 2013 in Cellular and Molecular Life Sciences
Verified
Journal Article
Open access
PDF file
LALuis A. Aparicio
Luis A. Aparicio
VAVanessa Abella
Vanessa Abella
MVManuel Valladares
Manuel Valladares
Angelica Figueroa Conde-ValvísAngelica Figueroa Conde-Valvís
Angelica Figueroa Conde-Valvís
Epithelial-to-mesenchymal transition (EMT), one of the crucial steps for carcinoma cells to acquire invasive capacity, results from the disruption of cell–cell contacts and the acquisition of a motile mesenchymal phenotype. Although the transcriptional events controlling EMT have been extensively studied, in recent years, several posttranscriptional mechanisms have emerged as critical in the regulation of EMT during tumor progression. In this review, we highlight the regulation of posttranscriptional events in EMT by RNA-binding proteins (RBPs). RBPs are responsible for controlling pre-mRNA splicing, capping, and polyadenylation, as well as mRNA export, turnover, localization, and translation. We discuss the most relevant aspects of RBPs controlling the metabolism of EMT-related mRNAs, and describe the implication of novel posttranscriptional mechanisms regulating EMT in response to different signaling pathways. Novel insight into posttranscriptional regulation of EMT by RBPs is uncovering new therapeutic targets in cancer invasion and metastasis.

1 April 2015 in Toxicology Letters
Verified
Journal Article
Closed access
VAVanessa Abella
Vanessa Abella
ASAnna Santoro
Anna Santoro
MSMorena Scotece
Morena Scotece
Javier Conde ArandaJavier Conde Aranda
Javier Conde Aranda
VLVerónica López-López
Verónica López-López
Oreste GualilloOreste Gualillo
Oreste Gualillo

7 August 2014 in Expert Review of Clinical Immunology
Verified
Journal Article
Closed access
Javier Conde ArandaJavier Conde Aranda
Javier Conde Aranda
MSMorena Scotece
Morena Scotece
VAVanessa Abella
Vanessa Abella
VLVerónica López
Verónica López
JPJesús Pino
Jesús Pino
Oreste GualilloOreste Gualillo
Oreste Gualillo
(2014). An update on leptin as immunomodulator. Expert Review of Clinical Immunology: Vol. 10, No. 9, pp. 1165-1170. doi: 10.1586/1744666X.2014.942289